Trial Profile
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Registrational; Therapeutic Use
- Acronyms STORM
- Sponsors Karyopharm Therapeutics
- 06 Dec 2023 According to an Antengene Corporation media release, the Pharmaceutical Administration Bureau of Macau has approved a NDA for XPOVIO (selinexor), applicable in combination with dexamethasone (Xd), for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs), an anti-CD38 monoclonal antibody.
- 26 Sep 2023 According to a Karyopharm Therapeutics media release, data from this trial will be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.
- 15 Jun 2023 Results of pooled analysis from 3 studies [MonumenTAL-1 (NCT03399799/NCT04636552), STORM (NCT02336815) and DREAMM-2 (NCT03525678)] comparing the effectiveness of talquetamab vs sel-dex and vs belamaf presented at the 28th Congress of the European Haematology Association.